COMPARATIVE CHEMOSENSITIVITY PROFILES IN 4 HUMAN OVARIAN-CARCINOMA CELL-LINES MEASURING ATP BIOLUMINESCENCE

被引:55
|
作者
PETRU, E [1 ]
SEVIN, BU [1 ]
PERRAS, J [1 ]
BOIKE, G [1 ]
RAMOS, R [1 ]
NGUYEN, H [1 ]
AVERETTE, HE [1 ]
机构
[1] UNIV MIAMI,SCH MED,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,MIAMI,FL 33101
关键词
D O I
10.1016/0090-8258(90)90032-G
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
cis-Platinum (DDP) and cyclophosphamide are commonly used for the treatment of ovarian cancer; however, survival remains poor. The degree of cytotoxicity of the standard antineoplastic agents DDP, 4-hydroperoxy-cyclophosphamide (4-OH-CTX), mitomycin C (MITOM C), vincristine (VCR), etoposide (VP-16), 5-fluorouracil (5-FU), cytosine arabinoside (ARA-C), and interferon (IF) in four representative ovarian cancer cell lines was studied using the ATP assay, which measures total cell kill. Cell lines CAOV-3, OVCAR-3, SKOV-3, and BG-1, which were derived from both pretreated and untreated patients, were exposed to six different concentrations for 90 min. On Day 7, intracellular ATP determinations were done. Sensitivity was defined as ≥50% cell kill at 0.5× peak plasma concentration as compared to controls. For 4-OH-CTX and ARA-C, 3 and 0.5 μg/ml were chosen as 0.5× reference values. For each drug in each cell line, a highly reproducible dose-response relationship was observed. CAOV-3 cells were sensitive to all drugs except DDP, ARA-C, and IF, and OVCAR-3 cells to all except DDP and IF. SKOV-3 cells were resistant to all agents except VCR, and BG-1 cells to all except MITOM C and 5-FU. The apparent heterogeneic response to antineoplastic agents observed in the above cell lines underscores the importance of assessing individual patients' sensitivity profiles before treatment. © 1990.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 50 条
  • [21] P-GLYCOPROTEIN EXPRESSION IN MULTIDRUG-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES
    BRADLEY, G
    NAIK, M
    LING, V
    CANCER RESEARCH, 1989, 49 (10) : 2790 - 2796
  • [22] ABNORMAL STRUCTURE AND EXPRESSION OF THE P53 GENE IN HUMAN OVARIAN-CARCINOMA CELL-LINES
    YAGINUMA, Y
    WESTPHAL, H
    CANCER RESEARCH, 1992, 52 (15) : 4196 - 4199
  • [23] RADIOSENSITIZATION BY CISPLATIN TREATMENT IN CISPLATIN-RESISTANT AND SENSITIVE HUMAN OVARIAN-CARCINOMA CELL-LINES
    RAAPHORST, GP
    WANG, G
    NG, CE
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1995, 7 (02) : 325 - 330
  • [24] ESTROGEN-RECEPTOR EXPRESSION AND EFFECTS OF TAMOXIFEN AGAINST HUMAN OVARIAN-CARCINOMA CELL-LINES
    HAWKES, MM
    LANGDON, SP
    LAWRIE, SS
    HAWKINS, RA
    MCDONALD, A
    TESDALE, A
    SMYTH, JF
    BRITISH JOURNAL OF CANCER, 1988, 58 (02) : 248 - 248
  • [25] MECHANISMS ASSOCIATED WITH DIFFERENTIAL CISPLATIN SENSITIVITY EXPRESSED BY 3 HUMAN OVARIAN-CARCINOMA CELL-LINES
    SHELLARD, SA
    HOSKING, LK
    HILL, BT
    BRITISH JOURNAL OF CANCER, 1989, 60 (03) : 474 - 474
  • [26] ESTABLISHMENT OF 6 OVARIAN-CARCINOMA CELL-LINES AND ESTIMATION OF DRUG SENSITIVITY INVITRO
    STEPHENS, IFD
    PLUMB, JA
    MACLEAN, AB
    KAYE, SB
    BRITISH JOURNAL OF CANCER, 1990, 62 (03) : 511 - 511
  • [27] DNA CROSS-LINKING AND PLATINUM RESISTANCE IN OVARIAN-CARCINOMA CELL-LINES
    BEATTIE, GJ
    HAYWARD, IP
    SMYTH, JF
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 202 - 202
  • [28] FLOW CYTOMETRIC AND MORPHOLOGICAL-STUDIES OF OVARIAN-CARCINOMA CELL-LINES AND XENOGRAFTS
    VANHAAFTENDAY, C
    RUSSELL, P
    RUGG, C
    WILLS, EJ
    TATTERSALL, MHN
    CANCER RESEARCH, 1983, 43 (08) : 3725 - 3731
  • [29] MORPHOLOGICAL, IMMUNOHISTOCHEMICAL AND BIOCHEMICAL-CHARACTERIZATION OF 6 NEWLY ESTABLISHED HUMAN OVARIAN-CARCINOMA CELL-LINES
    MOBUS, V
    GERHARZ, CD
    PRESS, U
    MOLL, R
    BECK, T
    MELLIN, W
    POLLOW, K
    KNAPSTEIN, PG
    KREIENBERG, R
    INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (01) : 76 - 84
  • [30] CHEMOSENSITIVITY OF ESTABLISHED HUMAN BLADDER-CARCINOMA CELL-LINES INVITRO
    HISAZUMI, H
    NAKAJIMA, K
    UCHIBAYASHI, T
    GANN, 1983, 74 (01): : 176 - 182